MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
7.50
-0.20 (-2.60%)
Apr 28, 2025, 4:00 PM EDT - Market closed
MiNK Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for MiNK Therapeutics stock have an average target of 37.5, with a low estimate of 35 and a high estimate of 40. The average target predicts an increase of 400.00% from the current stock price of 7.50.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2025.
Analyst Ratings
The average analyst rating for MiNK Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +366.67% | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $35 | Strong Buy | Maintains | $9 → $35 | +366.67% | Feb 25, 2025 |
| Baird | Baird | Buy Maintains $80 → $40 | Buy | Maintains | $80 → $40 | +433.33% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +1,100.00% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +1,100.00% | Oct 9, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
129.20K
EPS This Year
-2.68
from -2.86
EPS Next Year
-4.59
from -2.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 399,000 | n/a | ||
| Avg | n/a | 129,203 | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.59 | -0.91 | -0.78 | ||
| Avg | -2.68 | -4.59 | -1.75 | ||
| Low | -3.89 | -9.61 | -2.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.